An Act To Improve Oversight of Pharmaceutical Purchasing
Sec. 1. 22 MRSA §2699, sub-§1, ¶C-1 is enacted to read:
Sec. 2. 22 MRSA §2699, sub-§1, ¶D-1 is enacted to read:
(1) Advertising, publicizing, promoting or sharing information about a prescribed product;
(2) Identifying individuals to receive a message promoting use of a prescribed product, including but not limited to an advertisement, brochure or contact by a sales representative;
(3) Planning the substance of a sales representative visit or communication or the substance of an advertisement or other promotional message or document;
(4) Evaluating or compensating sales representatives;
(5) Identifying individuals to receive any form of gift, prescribed product sample, consultancy or other item, service, compensation or employment of value; and
(6) Advertising or promoting prescribed products directly to patients, including through refill reminders or information about alternative prescribed products.
Sec. 3. 22 MRSA §2699, sub-§1, ¶G is enacted to read:
Sec. 4. 22 MRSA §2699, sub-§6 is enacted to read:
Sec. 5. 22 MRSA §2699, sub-§8 is enacted to read:
Sec. 6. 22 MRSA §2699, sub-§9 is enacted to read:
(1) The data in the records is aggregated;
(2) The data in the records does not contain individually identifying information; and
(3) There is no reasonable basis for the belief that the data in the records can be used to obtain individually identifying information.
summary
This bill requires pharmacy benefits managers to register with the Department of Professional and Financial Regulation, Bureau of Insurance before entering into any contracts for pharmacy benefits management in the State. The bill also sets forth standards for audits conducted by pharmacy benefits managers. The bill requires the State Auditor to develop audit procedures to ensure state agencies that have pharmacy benefits management contracts are compliant with state law relating to pharmacy benefits management and prescription drug rebates. The bill also expands the privacy provisions applicable to pharmacy benefits managers to ensure that patient prescription information, even deidentified information, is not used directly by the pharmacy benefits manager or sold by or transferred to others for use in pharmaceutical marketing or by insurance companies in making benefits decisions.